Sector News

Former Wyeth Chairman and CE named Executive Chairman of Elucida Oncology

April 26, 2018
Life sciences

Elucida Oncology Inc., a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Robert A. Essner as its Executive Chairman.

Mr. Essner was Chairman and Chief Executive Officer for Wyeth, acquired by Pfizer in 2009. In his 32 years in the pharmaceutical industry Mr. Essner has held numerous high-level leadership roles that included Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA). He is Chairman of the not-for-profit Children’s Health Fund, and a Trustee of Mote Marine Laboratory, as well as Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in Healthcare Management.

Mr. Essner is also an Operating Executive for The Carlyle Group, and a member of the Board of Directors for Amicus Therapeutics and has just completed a 16-year term on the Board of Directors for MassMutual.

Isaac Blech, Vice Chairman of the Board of Directors of Elucida Oncology, commented, “All of us at Elucida are extremely pleased to bring an executive of Bob Essner’s stature into the company to help Elucida achieve its goal of becoming a leading precision medicine oncology company.”

“I welcome Bob to Elucida and look forward to his considerable experience being applied to the Elucida C-Dot platform as we bring to market first-in-class diagnostic and therapeutic products to positively impact the lives of cancer patients,” said Edward Rosen, Elucida’s President and Chief Executive Officer. “Bob Essner is a pivotal leader in the pharmaceutical industry. We are delighted to have Bob join us as Executive Chairman.”

“I am very excited to be part of what is being built at Elucida Oncology,” stated Mr. Essner. “Advancing innovation to change and save lives has been the core of my career for over 30 years. At Elucida, we have a remarkable first-in-class particle platform. This is a rare opportunity to make a compelling improvement to the world of precision oncology, in diagnostic and therapeutic applications. I am proud to be part of this effort and this team.”

Source: Elucida Oncology

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend